Datos Health COVID-19 Solution Employed at Rochester Regional Health

Datos Health is a provider of an automated remote care platform, together with Rochester-based consulting firm Strategic Interests, LLC. Today it was announced the successful deployment of the Datos COVID-19 solution at Rochester Regional Health.

The partnership is enabling Rochester Regional Health to more efficiently and safely monitor patients and healthcare workers exposed to or suffering from coronavirus, outside of the hospital setting.

“Given the current trajectory of the pandemic in major metropolitan areas, as COVID-19 continues to spread, hospitals may experience a surge in visitors, resulting in many health systems like ours quickly becoming overwhelmed and adding further burden on an already overstretched medical system,” said Bridgette Wiefling, MD, Senior VP for the Primary Care and Ambulatory Specialty Institute at Rochester Regional Health. “At Rochester Regional, we strive to provide optimal care to the patients in our community, while investing in our team members who put their lives on the line every day. This tool enables us to deliver great quality care and bring comfort to those who are on the frontline in fighting this disease.”

The Datos Health solution is specifically designed to support hospitals across the world to alleviate the strain on healthcare systems by helping to keep suspected coronavirus patients and those who are infected but do not require hospitalization, at home while still providing them with optimal care.

Rochester Regional is using the Datos Remote Care platform to monitor three groups of people:

  1. Staff at low risk of exposure, yet required to report their temperature twice daily for 14 days
  2. Staff displaying symptoms and tested positive for COVID-19
  3. Patients required to self-quarantine for 14 days due to displaying symptoms consistent with COVID-19 but having not met the testing criteria.

“Our remote care platform solution is helping healthcare systems like Rochester Regional to vastly improve communication between patients and care workers, providing reassurance during the challenging isolation period that they are still being cared for and will receive any further interventions if needed,” said Uri Bettesh, CEO of Datos Health. “For hospitals, this also provides the ability to safeguard employees, monitoring them for compliance and enabling them to return quickly to work once out of the isolation period.”

“This project is helping our client Rochester Regional Health to rapidly deploy critical and unique capabilities that can keep our community safe during these uncertain times, and we are honored to have played a supporting role in bringing together the dedicated clinicians and administrators at Rochester Regional with Datos’ dynamic team,” said Al Kinel, President, Strategic Interests. “It is remarkable that, in just a few short days, they were able to implement an innovative and efficient solution to preserve the dedicated medical staff and ensure the well-being of non-hospitalized patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”